Drug Shortage Oversight Remains Key GAO Concern As FDA Is Again Deemed “High-Risk”
This article was originally published in The Pink Sheet Daily
Executive Summary
Report again calls for improvement in oversight of medical device recalls by FDA, as well as for increased inspections of foreign establishments that make medical products for the U.S. market.